Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Empasiprubart IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 8 more
Conditions
B-cell Mediated Autoimmune Disorders
Interventions
Azercabtagene zapreleucel (azer-cel)
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Batoclimab
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
New Haven, Connecticut • Ormond Beach, Florida • Nicholasville, Kentucky + 2 more
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
riliprubart, Placebo, IVIg
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
32
States / cities
Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 27 more
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
5 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 12 more
Conditions
CIDP, Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Interferon Beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 9 more
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
NVG-2089
Drug
Lead sponsor
Nuvig Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Denton, Texas
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
H.P. Acthar® Gel
Drug
Lead sponsor
Mamatha Pasnoor, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Imeroprubart, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
33
States / cities
Tucson, Arizona • Carlsbad, California • Mission Hills, California + 28 more
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Intravenous Immunoglobulin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Johns Creek, Georgia • Chicago, Illinois • Kansas City, Kansas + 4 more
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Gamunex-C, Xembify
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 4 more
Recruiting Phase 1 Interventional

IVIG vs SCIG in CIDP

NCT05584631
Conditions
CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Intravenous immune globulin G, Subcutaneous immune globulin G
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
Interventions
Not listed
Lead sponsor
Charles M Knudson
Other
Eligibility
12 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions
IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Conditions
Chronic Inflammatory Demyelinating Neuropathy
Interventions
Alemtuzumab infusion
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Demyelinating Diseases, Paraproteinemias
Interventions
intravenous immunoglobulin (IVIg)
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Vasculitic Neuropathy (Disorder), Amyloidosis, Hereditary Neuropathy, Sarcoid Neuropathy
Interventions
Biopsy + Nerve Repair, Biopsy Only
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-411
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
La Jolla, California • San Francisco, California • Jacksonville, Florida + 10 more